At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. Moderna is a leader in the creation of the field of mRNA medicine. Through the ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...

Investors in Moderna Inc (Symbol ... publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would ...

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...